Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
621 to 640 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas. | Commun Biol | 2022 | 35396535 | PubTator, text mining | PubMed |
| ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. | Cell Rep | 2022 | 35385738 | PubTator, text mining | PubMed |
| Physical and functional interactome atlas of human receptor tyrosine kinases. | EMBO Rep | 2022 | 35384245 | PubTator, text mining | PubMed |
| A Nanobody-Based Toolset to Monitor and Modify the Mitochondrial GTPase Miro1. | Front Mol Biosci | 2022 | 35359597 | PubTator, text mining | PubMed |
| Case Report: ALK-Positive Histiocytosis With KIF5B-ALK Fusion in Cerebrum-Disseminated Lesions in a Child. | Front Oncol | 2022 | 35359354 | PubTator, text mining | PubMed |
| De novo heterozygous variants in KIF5B cause kyphomelic dysplasia. | Clin Genet | 2022 | 35342932 | PubTator, text mining | PubMed |
| Myeloproliferative neoplasm with basophilia and abnormality of platelet-derived growth factor receptor a translocation: a case report. | Blood Res | 2022 | 35342043 | PubTator, text mining | PubMed |
| Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion-Which Path Should We Follow? Case Reports and Literature Review. | J Clin Med | 2022 | 35329956 | PubTator, text mining | PubMed |
| Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report. | Anticancer Drugs | 2022 | 35324532 | PubTator, text mining | PubMed |
| Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer. | Cancer Med | 2022 | 35322575 | PubTator, text mining | PubMed |
| Mast cell granule motility and exocytosis is driven by dynamic microtubule formation and kinesin-1 motor function. | PLoS One | 2022 | 35316306 | PubTator, text mining | PubMed |
| SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report. | Front Oncol | 2022 | 35311071 | PubTator, text mining | PubMed |
| Host Molecules Regulating Neural Invasion of Zika Virus and Drug Repurposing Strategy. | Front Microbiol | 2022 | 35308394 | PubTator, text mining | PubMed |
| Deoxynivalenol triggers porcine intestinal tight junction disorder through hijacking SLC5A1 and PGC1α-mediated mitochondrial function. | Food Chem Toxicol | 2022 | 35307453 | PubTator, text mining | PubMed |
| Spatial regulation of endosomes in growing dendrites. | Dev Biol | 2022 | 35306006 | PubTator, text mining | PubMed |
| The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. | Nat Commun | 2022 | 35304457 | PubTator, text mining | PubMed |
| Activation of the CaMKII-Sarm1-ASK1-p38 MAP kinase pathway protects against axon degeneration caused by loss of mitochondria. | Elife | 2022 | 35285800 | PubTator, text mining | PubMed |
| RET receptor signaling: Function in development, metabolic disease, and cancer. | Proc Jpn Acad Ser B Phys Biol Sci | 2022 | 35283407 | PubTator, text mining | PubMed |
| Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment. | Front Oncol | 2022 | 35280798 | PubTator, text mining | PubMed |
| OpenCell: Endogenous tagging for the cartography of human cellular organization. | Science | 2022 | 35271311 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=32